New hopes for disease modification in Parkinson's Disease

NEUROPHARMACOLOGY

卷:171

Review

Poewe, Werner¹  Seppi, Klaus¹  Marini, Kathrin¹  Mahlknecht, Philipp¹ 

[1] Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria

关键词: Disease modifying;    Neuroprotection;    Parkinson's disease;    Risk screening;    Prevention;   

DOI  :  10.1016/j.neuropharm.2020.108085

来源: Elsevier

【 摘 要 】

To date, despite numerous clinical trials, no intervention has been demonstrated to modify the progression of Parkinson's disease (PD). However, over the past decades encouraging progress has been made towards a better understanding of molecular pathways relevant for the neurodegenerative process in PD. This is also based on new insights into the genetic architecture of the disease, revealing multiple novel targets for potentially disease-modifying interventions. Important achievements have also been made in the field of risk markers and combinations thereof, in the form of risk algorithms, will hopefully soon provide the possibility to identify affected individuals at yet prediagnostic or prodromal stages of the illness. Such phases of the disease would provide an ideal window for neuroprotection trials. Taken together, these developments offer hope that a breakthrough towards modifying the course of PD might be reached. In this article we summarize various approaches currently pursued in this quest. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.

【 授权许可】

Free